Lock­ing horns with Ab­b­Vie, J&J boasts post-TNF da­ta for next-gen drug Trem­fya in pso­ri­at­ic arthri­tis

In a bat­tle of gi­ants, J&J and Ab­b­Vie have locked horns for years with their com­pet­ing IL-23 drugs, both look­ing to take the helm as the next-gen im­munol­o­gy block­buster of choice. With a lead­ing two in­di­ca­tions un­der its belt, J&J’s Trem­fya is adding a new round of da­ta to the fold in pso­ri­at­ic arthri­tis, this time af­ter an­ti-TN­Fs like Hu­mi­ra.

Pso­ri­at­ic arthri­tis pa­tients with pri­or in­ad­e­quate re­sponse to TNF in­hibitors post­ed sig­nif­i­cant­ly bet­ter joint im­prove­ment and com­plete skin clear­ance on J&J’s Trem­fya com­pared with place­bo af­ter six months of ther­a­py, ac­cord­ing to da­ta from the Phase III/b COS­MOS study pre­sent­ed Wednes­day at the vir­tu­al EU­LAR meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER